Selank: calm without the benzodiazepine tax

The pitch, in plain terms: something that takes the edge off anxiety and leaves your head clear. Not sedated. Not slowed. Not building a habit you’ll have to unwind later. Anyone who’s taken a benzodiazepine for anxiety knows the trade — it works, then it charges you for it. Selank is Russia’s attempt at the calm without the invoice.

And there are real signs it might pull it off. Selank has been used in Russian psychiatry for over a decade, which makes it one of the very few peptides on the longevity menu with an actual anxiety authorisation behind it rather than a research-chemical guess. If it holds up the way the early record hints, that’s a big deal.

What it could actually do for you

Take anxiety down a notch. Keep your head clear. That’s the whole appeal — the good part of a benzodiazepine without the three or four bad parts stapled to it.

Selank works on the same calm-signalling chemistry benzos lean on — your serotonin and GABA systems — but comes at it from a different angle. The route is what matters. In the work so far, it doesn’t flip the sedation-and-dependence switch a benzo flips. The reported result: less anxiety, no fog, no next-morning hangover, no habit forming underneath. For a man who wants to be steadier under load without dulling the edge that makes him good at what he does, that’s about as on-target as an anxiety tool gets.

Built on a molecule you already make

Selank isn’t a lab compound bolted together from scratch. It’s built on tuftsin — a tiny four-part peptide your own immune system snips off an antibody. Russian chemists added a short three-part tail (the same trick they used on semax) that makes it last hours instead of minutes and steers it toward the brain. So the raw material is something your body already produces. Nothing exotic. The engineering just gave it staying power and somewhere to go.

The animal work lines up behind the story. In rats, Semenova and colleagues (2009) showed selank rebuilding serotonin signalling in brains that had been chemically stripped of it — the exact chemistry a steady mood runs on. Separate rat work from Konstantinopolsky and colleagues (2022) has it easing the distress of morphine withdrawal. Different models, same direction: a genuine calming effect that runs through a different door than a benzodiazepine uses.

The honest boundary

Now the boundary, because the forums oversell this one badly.

Almost everything we know about selank in actual people comes from Russia — published in Russian, in study designs Western regulators don’t treat as the last word. The two most-cited human studies, Zozulia and colleagues (2008) in 62 adults with anxiety and Medvedev and colleagues (2014), each put selank head-to-head against a benzodiazepine and reported no significant difference in anxiety relief, with fewer side effects on the selank side.

Read those for what they are. Comparisons against another drug, not against a placebo. Open-label, modest sample sizes, in patients already diagnosed with anxiety — not healthy men microdosing before a stressful week. That’s real evidence; comparative work counts. It just isn’t the same as a modern placebo-controlled trial, and nobody has run one. The 2026 Frontiers in Aging review by Mavrych and colleagues files selank exactly where it belongs: real signal, real gaps — no long-term safety data in healthy users, no modern dosing studies, no independent Western replication.

So this is hope with your eyes open. Two decades of Russian clinical use is a serious real-world signal — not the same thing as the trial that would settle it, and that trial hasn’t been done. If selank turns out as good as the Russian record hints, it’s a genuinely exciting tool. The one thing standing between it and a straight recommendation is a study nobody has paid to run.

Where the regulators sit

Selank isn’t tangled up in the FDA’s compounding review at all — not the July 2026 PCAC wave, not the early-2027 one, and it’s never faced a PCAC vote. It simply sits outside the process. What a PCAC review actually decides is a longer story, told in what a PCAC review actually is. For now, selank in the US is a research chemical: no FDA approval, no application on file.

Anti-doping is stricter than the printed list looks. Selank isn’t named outright on the WADA prohibited list, but the non-approved-substances category is written broadly enough to catch it. If you get tested, treat it as off-limits — the missing name is not a clearance.

What happens next

Two things are true at once. The Russian record is real, and on its own it isn’t enough. The mechanism is genuinely interesting, and the modern trial that would prove it is still unwritten.

What’s missing isn’t the molecule. It’s the supervision. Selank’s entire safety case in Russia rests on being prescribed and monitored by a physician — the exact part the grey market strips out when it ships you a nasal spray from a research-chemical checkout. The version worth waiting for looks nothing like that: a doctor who knows your history, a licensed US pharmacy that makes it to spec, and a lab result on the bottle before it reaches you. Wolverine Health is being built to be that version, and it can’t open until the regulation moves — which is the honest reason it hasn’t yet. Put your email down and we’ll come find you the moment a supervised, tested selank is something you can actually get.